North America | Western Europe | Australia/South Africa | Japan | Asia | Eastern Europe/Russia | South America/Mexico | Total sample | |
---|---|---|---|---|---|---|---|---|
N (%) | 1,884 (40.1) | 981 (20.9) | 237 (5.1) | 435 (9.3) | 339 (7.2) | 408 (8.7) | 410 (8.7) | 4,694 (100) |
Age, yr (mean ± SD) | 75.1 ± 8.3EE,AS,JP,AU,WE | 71.9 ± 7.8SA,JP | 72.9 ± 7.4SA,EE,NA | 73.4 ± 7.6SA,NA | 72.1 ± 7.6SA,NA | 70.7 ± 7.8SA,AU,NA | 75.4 ± 7.7EE,AS,JP,AU,WE | 73.6 ± 8.1 |
Female sex, n (%) | 986 (52.3)SA,EE,JP | 503 (51.3) SA,EE,JP | 128 (54.0)SA | 276 (63.5)WE,NA | 191 (56.3) | 255 (62.5)WE,NA | 279 (68.1)AU,WE,NA | 2,618 (55.8) |
Height, cm (mean ± SD) | 166.5 ± 10.7SA,EE,AS,JP | 166.1 ± 9.8SA,EE,AS,JP | 166.8 ± 9.7SA,EE,AS,JP | 154.6 ± 8.9SA,EE,AS,AU,WE,NA | 158.2 ± 8.6EE,JP,AU,WE,NA | 163.4 ± 9.1SA,AS,JP,AU,WE,NA | 160.0 ± 9.1EE,JP,AU,WE,NA | 163.9 ± 10.7 |
Weight, kg (mean ± SD) | 73.2 ± 15.7SA,EE,AS,JP,WE | 70.2 ± 12.7SA,AS,JP,NA | 70.7 ± 13.1SA,AS,JP | 53.1 ± 10.0SA,EE,AS,AU,WE,NA | 58.5 ± 9.7SA,EE,JP,AU,WE,NA | 68.8 ± 12.6AS,JP,NA | 66.6 ± 12.5AS,JP,AU,WE,NA | 68.6 ± 15.0 |
Body mass index, kg/m2 (mean ± SD) | 26.3 ± 4.7AS,JP,WE | 25.4 ± 3.8AS,JP,NA | 25.4 ± 4.1AS,JP | 22.1 ± 3.1SA,EE,AS,AU,WE,NA | 23.3 ± 3.1SA,EE,JP,AU,WE,NA | 25.4 ± 3.8AS,JP | 26.0 ± 4.3AS,JP | 25.4 ± 4.4 |
Years of education (mean ± SD) | 14.1 ± 3.3SA,EE,AS,JP,AU,WE | 11.2 ± 4.2SA,EE,AS,NA | 12.1 ± 3.5SA,AS,WE,NA | 11.7 ± 2.7SA,AS,NA | 9.5 ± 4.7EE,JP,AU,WE,NA | 11.9 ± 3.8SA,AS,WE,NA | 8.9 ± 4.5EE,JP,AU,WE,NA | 12.2 ± 4.1 |
APOE ε4 genotype carriers, n (%) | 1,086 (63.2)SA,EE,AS,JP | 494 (63.3)SA,EE,AS,JP | 149 (63.7)SA | 220 (51.9)WE,NA | 93 (48.4)WE,NA | 191 (51.1)WE,NA | 189 (49.5)AU,WE,NA | 2,422 (59.0) |
Years since symptom onset (mean ± SD) | 4.8 ± 2.6EE,AS,JP | 4.6 ± 2.5EE,JP | 4.7 ± 2.8EE,JP | 3.7 ± 2.3SA,AS,AU,WE,NA | 4.2 ± 2.4JP,NA | 3.9 ± 2.2SA,AU,WE,NA | 4.5 ± 2.4EE,JP | 4.5 ± 2.5 |
Years since diagnosis (mean ± SD) | 2.5 ± 2.1EE,AS,JP,AU,WE | 2.1 ± 1.8EE,JP,NA | 2.0 ± 1.8EE,NA | 1.7 ± 1.5SA,WE,NA | 2.0 ± 1.9SA,EE,NA | 1.5 ± 1.5SA,AS,AU,WE,NA | 2.4 ± 1.9EE,AS,JP | 2.2 ± 1.9 |
Proportion taking any anti-AD medication, n (%) | 1,677 (89.0) EE,AS,AU | 902 (92.0)SA,EE,AS,AU | 172 (72.6)JP,WE,NA | 389 (89.4)AS,AU | 274 (80.8)WE,NA | 302 (74.0)JP,WE,NA | 342 (83.4)WE | 4,058 (86.5) |
Proportion taking dual anti-AD therapy, n (%) | 894 (47.5)SA,EE,AS,JP,AU,WE | 147 (15.0)SA,AS,JP,AU,NA | 16 (6.8)SA,JP,WE,NA | 3 (0.7)SA,EE,AS,AU,WE,NA | 21 (6.2)SA,EE,JP,WE,NA | 58 (14.2)SA,AS,JP,NA | 117 (28.5)EE,AS,JP,AU,WE,NA | 1,256 (26.8) |
Proportion enrolling with spouse study partner, n (%) | 1,318 (70.4)SA,EE,AS | 719 (73.7)SA,EE,AS | 178 (75.7)SA,EE,AS | 279 (64.6)SA,EE,AS | 172 (50.9)JP,AU,WE,NA | 163 (40.1)JP,AU,WE,NA | 174 (42.7)JP,AU,WE,NA | 3,003 (64.4) |
Proportion enrolling with adult child study partner, n (%) | 374 (20.0) | 192 (19.7) | 36 (15.3) | 116 (26.9) | 136 (40.2) | 203 (49.9) | 162 (39.7) | 1,219 (26.1) |
Proportion enrolling with other study partner, n (%) | 179 (9.6) | 64 (6.6) | 21 (8.9) | 37 (8.6) | 30 (8.9) | 41 (10.1) | 72 (17.7) | 444 (9.5) |